Injectable Drug Market Overview for 2024 to 2034

The injectable drug market is evaluated to be sized at US$ 5,97,980.6 million in 2024. During the period from 2024 to 2034, the market is expected to progress at a solid clip, registering a CAGR of 5.8%. By 2034, the injectable drug market is anticipated to have reached a value of US$ 9,91,631.3 million.

Global Injectable Drug Market Overview

  • Injectable drugs are associated with effective treatment of ailments as well as faster recovery times and thus preference for them is increasing among patients.
  • Injectable drugs are considered practical in emergencies and as the capabilities of hospitals and medical workers to handle emergency situations increase, injectable drugs are seeing more application.
  • Rise in the number of diabetes patients is leading to demand for insulin in injectable form to capitulate.
  • Medical professionals recommending injections to their patients instead of oral medicine, for their effectiveness in getting rid of common problems like fever and cold, is influencing the market positively.
  • Minimally invasive procedures are receiving the vote of confidence from a considerable number of patients and thus injectable drugs through injections are entering more bloodstreams.
Attributes Details
Injectable Drug Market Value for 2024 US$ 5,97,980.6 million
Projected Market Value for 2034 US$ 9,91,631.3 million
Value-based CAGR of Market for 2024 to 2034 5.8%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Trends in the Prescription Delivery Services Market

  • With the development of new infectious diseases putting the spotlight on vaccines, injectable drugs are increasingly being called upon to treat diseases permanently, or at least for the long term.
  • Biotechnology is enabling the development of exciting new injectable drugs, for example, Etanercept (Enbrel) for rheumatoid arthritis, and these new medications are making sure the market remains fresh.
  • Injection of new biologics drugs into the market like Imjudo (tremelimumab) and Elahere (mirvetuximab soravtansine) is keeping the demand for injectable drugs flowing.
  • New drugs receiving approvals from regulatory bodies like the USA Food and Drug Administration (FDA) in increasing measure keeping the product line moving for market players.
  • Sheer surge in the number of people getting affected by diseases like cancer and cardiovascular diseases is necessitating the administration of injectable drugs.
  • Fear of needles among a considerable number of people, especially children, continues to be a rudimentary limiting factor for the market.
  • Aversion to side effects of injectable drugs sees patients turn to other forms of treatment, constraining the growth of the market.

Category-wise Outlook

Monoclonal antibodies stand atop the pile in the product type segment. Intravenous (IV) injections remain the predominant mode of administration.

Rising Cancer Cases See Dependency on Monoclonal Antibodies Increase

Monoclonal antibodies are expected to account for 25.2% of the market share in 2024. Some of the factors influencing the increase in demand for monoclonal antibodies are:

  • Alarming number of patients getting diagnosed with cancer is increasing the growing adoption of injectable monoclonal antibodies like Alemtuzumab and Bevacizumab.
  • Various diseases like Crohn’s disease and ankylosing spondylitis come under the scanner of monoclonal antibodies. Injectable monoclonal antibodies like infliximab and adalimumab are thus seeing more frequent use.
Attributes Details
Top Product Type Monoclonal Antibody
Market Share (2024) 10.8%

Direct Approach of Intravenous (IV) Injections Preffered for Treatment

Intravenous (IV) injections are anticipated to account for 48.3% of the market share in 2024. Some of the reasons for the progress of intravenous (IV) injections are:

  • Direct penetration of intravenous (IV) injections makes doctors and patients partial to them, with the direct route assuring greater absorption of the drug.
  • Pain relief medications, antibodies, and more are all being delivered through the IV mode for the fast way the injection lets out the drug into the bloodstream. As demand for these types of drugs climbs, IV injections too are being administered more frequently.
Attributes Details
Top Route of Administration Intravenous (IV) injections
Market Share (2024) 48.3%
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-Wise Analysis

Problems like the aging population and the rise in mental health problems are seeing the healthcare sector develop in Europe. The rise in patients is invariably leading to greater demand for injectable drugs.

The Europe Medicines Agency (EMA) approving injectable drugs for marketing and distribution at a fair rate is propelling the market in Europe. Governments in Europe striving to make healthcare affordable in Europe is also helping the market’s development.

Countries CAGR (2024 to 2034)
Spain 4.0%
United Kingdom 3.0%
Italy 3.3%
France 3.4%
Germany 2.5%

Spanish Startups and Companies Attracting Foreign Investment

The CAGR of the market for the forecast period in Spain is anticipated to be 4.0%. Some of the factors influencing the growth of the market in the country are:

  • Spanish startups and small-size players are advancing with the aid of foreign investment, or in some cases, like with the GES Group, getting taken over by foreign players.
  • Injectable drugs for the treatment of schizophrenia are seeing greater adoption in Spain as cases of the ailment increase in the country.

Diabetes Treatment with the Help of Newly Developed Injectable Drugs Advancing in the United Kingdom

The market is expected to register a CAGR of 3.0% in the United Kingdom through 2034. Some of the factors responsible for the growth of the market are:

  • Face of diabetes treatment is changing with the development of new injectable drugs. For example, it was announced in January 2024 that the Mounjaro device from Eli Lilly, with the injectable drug tirzepatide, would be made available in the United Kingdom for the treatment of type 2 diabetes.
  • Cancer treatment is getting new facets in the United Kingdom with the help of injectable drugs. For example, in 2023, Atezolizumab was approved as a cancer treatment, with the effect of cutting treatment time as low as seven minutes.

Expansion of Medicine Producing Facilities Conducive to Growth of the Market in France

The market is expected to progress at a CAGR of 3.4% in France for the forecast period. Some factors influencing the progress are:

  • France’s injectable drug-producing capabilities are developing fast. For example, CARBOGEN AMCIS opened a new facility for the production of sterile injectable drugs in France in 2023.
  • Small-scale players and startups are teaming up with both local and foreign giants to increase their scope in the country.

Foreign Companies Expanding Footprint in Italy

The market is expected to progress at a CAGR of 3.3% in Italy throughout the forecast period. Some factors influencing the progress are:

  • Foreign giants in the market are expanding their footprint in Italy. For example, in 2020, Thermo Fisher announced its intention to open a new sterile drug manufacturing facility in Monza, Italy.
  • Infectious diseases proliferating is necessitating the use of injectable drugs in Italy.

Germany’s Aging Population Requiring Greater Number of Injectable Drugs

The market is expected to progress at a CAGR of 2.5% in Germany. Some factors influencing the progress are:

  • With the population of Germany aging fast, injectable drugs are being administered in greater measure in the country.
  • Market giants are making their way to Germany fast after sensing the market opportunities. For example, American company Eli Lilly and Co. announced plans to open its first production facility in Germany in November 2023.

Competitive Landscape in the Injectable Drug Market

The injectable drug market is moderately fragmented. Multinational companies are focusing on expanding production, while small-scale companies are looking for investments to remain competitive.

Pfizer Inc.’s personalized approach towards patients is seeing the company develop targeted injectable drugs. Other companies in the market are establishing partnerships between themselves to develop and advertise new products.

Recent Developments in the Injectable Drug Market

  • In May 2023, French company MedinCell received approval from the FDA for its Uzedy (risperidone) injectable treatment.
  • In August 2021, Cadila Healthcare partnered with Italian firm CHEMI SpA for the launch of its generic drug in the United States.
  • In October 2020, EMA granted approvals for the marketing of two new injectable drugs called Rekambys (rilpivirine) and Vocabria injection (cabotegravir).

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Key Companies in the Prescription Delivery Service Market

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • AstraZeneca Plc
  • Merck & Co., Inc.
  • Viatris + Mylan N.V
  • Cipla Inc.
  • Dr Reddy’s Laboratories Ltd.
  • Samsung Biologics
  • Abbott Laboratories
  • Amgen Incorporated
  • Baxter International Incorporated
  • Becton Dickinson and Company
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • Roche Holding Limited

Key Coverage in the Injectable Drug Market Report

  • Injectable Drug Market Demand Analysis
  • Injectable Drug Market Growth Assessment
  • Global Injectable Drug Market Size and Share Report
  • Sales Analysis Of Sterile Injectable Drugs
  • Coverage of Opportunities For Injectable Drug Manufacturers
  • Injectable Drug Market Share in Overall Medicine industry

Key Segments

By Product:

  • Monoclonal Antibody
  • Immunoglobulin
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Peptide Antibiotics
  • Vaccines
  • Small Molecule Antibiotics
  • Chemotherapy Agents
  • Others

By Application:

  • Oncology
  • Infectious Diseases
  • Diabetes
  • Blood disorders
  • Hormonal Disorders
  • Musculoskeletal Disorders
  • CNS Diseases
  • Pain Management
  • Cardiovascular Diseases

By Molecule Type:

  • Small Molecule
  • Large Molecule

By Route of Administration:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the Injectable Drug Market?

The size of the injectable drug market is estimated to be US$ 5,97,980.6 million in 2024.

At What Rate is the Injectable Drug Market Expected to Grow?

The injectable drug market is expected to increase at a CAGR of 5.8% over the forecast period.

What is the Scope of Injectable Drug in the United Kingdom?

The injectable drug market is expected to register a CAGR of 3.0% in the United Kingdom over the period from 2024 to 2034.

What is the Forecast of the Injectable Drug Market?

The injectable drug market is forecasted to reach a size of US$ 9,91,631.3 million by 2034.

What is the Trend in the Injectable Drug Industry?

Use of biotechnology for developing new drugs and the rising importance of vaccines are two of the trends in the injectable drug industry.

Which are the Key Companies in the Injectable Drug Market?

Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., and Sun Pharmaceutical Industries Ltd. are some of the prominent companies in the injectable drug market.

What is the Top Product Type in the Injectable Drug Market?

Monoclonal antibodies are the top product type in the injectable drug market, with an estimated market share of 10.8% in 2024.

What is the Scope of Injectable Drug in Germany?

The injectable drug market is expected to register a CAGR of 2.5% in Germany over the period from 2024 to 2034.

Table of Content
1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Product Life Cycle Analysis
    3.5. Supply Chain Analysis
        3.5.1. Supply Side Participants and their Roles
            3.5.1.1. Manufacturer
            3.5.1.2. Mid-Level Participants (Traders)
            3.5.1.3. Wholesalers and Distributors
        3.5.2. Value Added and Value Created at Node in the Supply Chain
        3.5.3. List of Raw Material Suppliers
        3.5.4. List of Existing and Potential Buyer’s
    3.6. Investment Feasibility Matrix
    3.7. Value Chain Analysis
        3.7.1. Profit Margin Analysis
        3.7.2. Wholesalers and Distributors
        3.7.3. Retailers
    3.8. PESTLE and Porter’s Analysis
    3.9. Regulatory Landscape
        3.9.1. By Key Regions
        3.9.2. By Key Countries
    3.10. Regional Parent Market Outlook
    3.11. Production and Consumption Statistics
    3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
    4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2019 to 2023
    4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2024 to 2034
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product, 2019 to 2023
    5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product, 2024 to 2034
        5.3.1. Monoclonal Antibodies
        5.3.2. Immunoglobulin
        5.3.3. Cytokines
        5.3.4. Insulin
        5.3.5. Peptide Hormones
        5.3.6. Blood Factors
        5.3.7. Peptide Antibiotics
        5.3.8. Vaccines
        5.3.9. Small Molecule Antibiotics
        5.3.10. Chemotherapy Agents
        5.3.11. Others
    5.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023
    5.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application, 2019 to 2023
    6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application, 2024 to 2034
        6.3.1. Oncology
        6.3.2. Infectious Diseases
        6.3.3. Diabetes
        6.3.4. Blood disorders
        6.3.5. Hormonal Disorders
        6.3.6. Musculoskeletal Disorders
        6.3.7. CNS Diseases
        6.3.8. Pain Management
        6.3.9. Cardiovascular Diseases
    6.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023
    6.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Molecule Type
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Molecule Type, 2019 to 2023
    7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Molecule Type, 2024 to 2034
        7.3.1. Small Molecules
        7.3.2. Large Molecules
    7.4. Y-o-Y Growth Trend Analysis By Molecule Type, 2019 to 2023
    7.5. Absolute $ Opportunity Analysis By Molecule Type, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
    8.1. Introduction / Key Findings
    8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Route of Administration, 2019 to 2023
    8.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Route of Administration, 2024 to 2034
        8.3.1. Intravenous (IV)
        8.3.2. Intramuscular (IM)
        8.3.3. Subcutaneous (SC)
    8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023
    8.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
    9.1. Introduction / Key Findings
    9.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Distribution Channel, 2019 to 2023
    9.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2024 to 2034
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Drug Stores
        9.3.4. Online Pharmacies
    9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
    9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
    10.1. Introduction
    10.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2019 to 2023
    10.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2024 to 2034
        10.3.1. North America
        10.3.2. Latin America
        10.3.3. Western Europe
        10.3.4. Eastern Europe
        10.3.5. South Asia and Pacific
        10.3.6. East Asia
        10.3.7. Middle East and Africa
    10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
    11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
        11.2.1. By Country
            11.2.1.1. USA
            11.2.1.2. Canada
        11.2.2. By Product
        11.2.3. By Application
        11.2.4. By Molecule Type
        11.2.5. By Route of Administration
        11.2.6. By Distribution Channel
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Product
        11.3.3. By Application
        11.3.4. By Molecule Type
        11.3.5. By Route of Administration
        11.3.6. By Distribution Channel
    11.4. Key Takeaways
12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
    12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
        12.2.1. By Country
            12.2.1.1. Brazil
            12.2.1.2. Mexico
            12.2.1.3. Rest of Latin America
        12.2.2. By Product
        12.2.3. By Application
        12.2.4. By Molecule Type
        12.2.5. By Route of Administration
        12.2.6. By Distribution Channel
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Product
        12.3.3. By Application
        12.3.4. By Molecule Type
        12.3.5. By Route of Administration
        12.3.6. By Distribution Channel
    12.4. Key Takeaways
13. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
    13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
        13.2.1. By Country
            13.2.1.1. Germany
            13.2.1.2. UK
            13.2.1.3. France
            13.2.1.4. Spain
            13.2.1.5. Italy
            13.2.1.6. Rest of Western Europe
        13.2.2. By Product
        13.2.3. By Application
        13.2.4. By Molecule Type
        13.2.5. By Route of Administration
        13.2.6. By Distribution Channel
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Product
        13.3.3. By Application
        13.3.4. By Molecule Type
        13.3.5. By Route of Administration
        13.3.6. By Distribution Channel
    13.4. Key Takeaways
14. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
    14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
        14.2.1. By Country
            14.2.1.1. Poland
            14.2.1.2. Russia
            14.2.1.3. Czech Republic
            14.2.1.4. Romania
            14.2.1.5. Rest of Eastern Europe
        14.2.2. By Product
        14.2.3. By Application
        14.2.4. By Molecule Type
        14.2.5. By Route of Administration
        14.2.6. By Distribution Channel
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Product
        14.3.3. By Application
        14.3.4. By Molecule Type
        14.3.5. By Route of Administration
        14.3.6. By Distribution Channel
    14.4. Key Takeaways
15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
    15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
        15.2.1. By Country
            15.2.1.1. India
            15.2.1.2. Bangladesh
            15.2.1.3. Australia
            15.2.1.4. New Zealand
            15.2.1.5. Rest of South Asia and Pacific
        15.2.2. By Product
        15.2.3. By Application
        15.2.4. By Molecule Type
        15.2.5. By Route of Administration
        15.2.6. By Distribution Channel
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Product
        15.3.3. By Application
        15.3.4. By Molecule Type
        15.3.5. By Route of Administration
        15.3.6. By Distribution Channel
    15.4. Key Takeaways
16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    16.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
    16.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
        16.2.1. By Country
            16.2.1.1. China
            16.2.1.2. Japan
            16.2.1.3. South Korea
        16.2.2. By Product
        16.2.3. By Application
        16.2.4. By Molecule Type
        16.2.5. By Route of Administration
        16.2.6. By Distribution Channel
    16.3. Market Attractiveness Analysis
        16.3.1. By Country
        16.3.2. By Product
        16.3.3. By Application
        16.3.4. By Molecule Type
        16.3.5. By Route of Administration
        16.3.6. By Distribution Channel
    16.4. Key Takeaways
17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    17.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
    17.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
        17.2.1. By Country
            17.2.1.1. GCC Countries
            17.2.1.2. South Africa
            17.2.1.3. Israel
            17.2.1.4. Rest of MEA
        17.2.2. By Product
        17.2.3. By Application
        17.2.4. By Molecule Type
        17.2.5. By Route of Administration
        17.2.6. By Distribution Channel
    17.3. Market Attractiveness Analysis
        17.3.1. By Country
        17.3.2. By Product
        17.3.3. By Application
        17.3.4. By Molecule Type
        17.3.5. By Route of Administration
        17.3.6. By Distribution Channel
    17.4. Key Takeaways
18. Key Countries Market Analysis
    18.1. USA
        18.1.1. Pricing Analysis
        18.1.2. Market Share Analysis, 2023
            18.1.2.1. By Product
            18.1.2.2. By Application
            18.1.2.3. By Molecule Type
            18.1.2.4. By Route of Administration
            18.1.2.5. By Distribution Channel
    18.2. Canada
        18.2.1. Pricing Analysis
        18.2.2. Market Share Analysis, 2023
            18.2.2.1. By Product
            18.2.2.2. By Application
            18.2.2.3. By Molecule Type
            18.2.2.4. By Route of Administration
            18.2.2.5. By Distribution Channel
    18.3. Brazil
        18.3.1. Pricing Analysis
        18.3.2. Market Share Analysis, 2023
            18.3.2.1. By Product
            18.3.2.2. By Application
            18.3.2.3. By Molecule Type
            18.3.2.4. By Route of Administration
            18.3.2.5. By Distribution Channel
    18.4. Mexico
        18.4.1. Pricing Analysis
        18.4.2. Market Share Analysis, 2023
            18.4.2.1. By Product
            18.4.2.2. By Application
            18.4.2.3. By Molecule Type
            18.4.2.4. By Route of Administration
            18.4.2.5. By Distribution Channel
    18.5. Germany
        18.5.1. Pricing Analysis
        18.5.2. Market Share Analysis, 2023
            18.5.2.1. By Product
            18.5.2.2. By Application
            18.5.2.3. By Molecule Type
            18.5.2.4. By Route of Administration
            18.5.2.5. By Distribution Channel
    18.6. UK
        18.6.1. Pricing Analysis
        18.6.2. Market Share Analysis, 2023
            18.6.2.1. By Product
            18.6.2.2. By Application
            18.6.2.3. By Molecule Type
            18.6.2.4. By Route of Administration
            18.6.2.5. By Distribution Channel
    18.7. France
        18.7.1. Pricing Analysis
        18.7.2. Market Share Analysis, 2023
            18.7.2.1. By Product
            18.7.2.2. By Application
            18.7.2.3. By Molecule Type
            18.7.2.4. By Route of Administration
            18.7.2.5. By Distribution Channel
    18.8. Spain
        18.8.1. Pricing Analysis
        18.8.2. Market Share Analysis, 2023
            18.8.2.1. By Product
            18.8.2.2. By Application
            18.8.2.3. By Molecule Type
            18.8.2.4. By Route of Administration
            18.8.2.5. By Distribution Channel
    18.9. Italy
        18.9.1. Pricing Analysis
        18.9.2. Market Share Analysis, 2023
            18.9.2.1. By Product
            18.9.2.2. By Application
            18.9.2.3. By Molecule Type
            18.9.2.4. By Route of Administration
            18.9.2.5. By Distribution Channel
    18.10. Poland
        18.10.1. Pricing Analysis
        18.10.2. Market Share Analysis, 2023
            18.10.2.1. By Product
            18.10.2.2. By Application
            18.10.2.3. By Molecule Type
            18.10.2.4. By Route of Administration
            18.10.2.5. By Distribution Channel
    18.11. Russia
        18.11.1. Pricing Analysis
        18.11.2. Market Share Analysis, 2023
            18.11.2.1. By Product
            18.11.2.2. By Application
            18.11.2.3. By Molecule Type
            18.11.2.4. By Route of Administration
            18.11.2.5. By Distribution Channel
    18.12. Czech Republic
        18.12.1. Pricing Analysis
        18.12.2. Market Share Analysis, 2023
            18.12.2.1. By Product
            18.12.2.2. By Application
            18.12.2.3. By Molecule Type
            18.12.2.4. By Route of Administration
            18.12.2.5. By Distribution Channel
    18.13. Romania
        18.13.1. Pricing Analysis
        18.13.2. Market Share Analysis, 2023
            18.13.2.1. By Product
            18.13.2.2. By Application
            18.13.2.3. By Molecule Type
            18.13.2.4. By Route of Administration
            18.13.2.5. By Distribution Channel
    18.14. India
        18.14.1. Pricing Analysis
        18.14.2. Market Share Analysis, 2023
            18.14.2.1. By Product
            18.14.2.2. By Application
            18.14.2.3. By Molecule Type
            18.14.2.4. By Route of Administration
            18.14.2.5. By Distribution Channel
    18.15. Bangladesh
        18.15.1. Pricing Analysis
        18.15.2. Market Share Analysis, 2023
            18.15.2.1. By Product
            18.15.2.2. By Application
            18.15.2.3. By Molecule Type
            18.15.2.4. By Route of Administration
            18.15.2.5. By Distribution Channel
    18.16. Australia
        18.16.1. Pricing Analysis
        18.16.2. Market Share Analysis, 2023
            18.16.2.1. By Product
            18.16.2.2. By Application
            18.16.2.3. By Molecule Type
            18.16.2.4. By Route of Administration
            18.16.2.5. By Distribution Channel
    18.17. New Zealand
        18.17.1. Pricing Analysis
        18.17.2. Market Share Analysis, 2023
            18.17.2.1. By Product
            18.17.2.2. By Application
            18.17.2.3. By Molecule Type
            18.17.2.4. By Route of Administration
            18.17.2.5. By Distribution Channel
    18.18. China
        18.18.1. Pricing Analysis
        18.18.2. Market Share Analysis, 2023
            18.18.2.1. By Product
            18.18.2.2. By Application
            18.18.2.3. By Molecule Type
            18.18.2.4. By Route of Administration
            18.18.2.5. By Distribution Channel
    18.19. Japan
        18.19.1. Pricing Analysis
        18.19.2. Market Share Analysis, 2023
            18.19.2.1. By Product
            18.19.2.2. By Application
            18.19.2.3. By Molecule Type
            18.19.2.4. By Route of Administration
            18.19.2.5. By Distribution Channel
    18.20. South Korea
        18.20.1. Pricing Analysis
        18.20.2. Market Share Analysis, 2023
            18.20.2.1. By Product
            18.20.2.2. By Application
            18.20.2.3. By Molecule Type
            18.20.2.4. By Route of Administration
            18.20.2.5. By Distribution Channel
    18.21. GCC Countries
        18.21.1. Pricing Analysis
        18.21.2. Market Share Analysis, 2023
            18.21.2.1. By Product
            18.21.2.2. By Application
            18.21.2.3. By Molecule Type
            18.21.2.4. By Route of Administration
            18.21.2.5. By Distribution Channel
    18.22. South Africa
        18.22.1. Pricing Analysis
        18.22.2. Market Share Analysis, 2023
            18.22.2.1. By Product
            18.22.2.2. By Application
            18.22.2.3. By Molecule Type
            18.22.2.4. By Route of Administration
            18.22.2.5. By Distribution Channel
    18.23. Israel
        18.23.1. Pricing Analysis
        18.23.2. Market Share Analysis, 2023
            18.23.2.1. By Product
            18.23.2.2. By Application
            18.23.2.3. By Molecule Type
            18.23.2.4. By Route of Administration
            18.23.2.5. By Distribution Channel
19. Market Structure Analysis
    19.1. Competition Dashboard
    19.2. Competition Benchmarking
    19.3. Market Share Analysis of Top Players
        19.3.1. By Regional
        19.3.2. By Product
        19.3.3. By Application
        19.3.4. By Molecule Type
        19.3.5. By Route of Administration
        19.3.6. By Distribution Channel
20. Competition Analysis
    20.1. Competition Deep Dive
        20.1.1. Pfizer Inc.
            20.1.1.1. Overview
            20.1.1.2. Product Portfolio
            20.1.1.3. Profitability by Market Segments
            20.1.1.4. Sales Footprint
            20.1.1.5. Strategy Overview
                20.1.1.5.1. Marketing Strategy
                20.1.1.5.2. Product Strategy
                20.1.1.5.3. Channel Strategy
        20.1.2. Teva Pharmaceutical Industries Ltd.
            20.1.2.1. Overview
            20.1.2.2. Product Portfolio
            20.1.2.3. Profitability by Market Segments
            20.1.2.4. Sales Footprint
            20.1.2.5. Strategy Overview
                20.1.2.5.1. Marketing Strategy
                20.1.2.5.2. Product Strategy
                20.1.2.5.3. Channel Strategy
        20.1.3. Sanofi S.A.
            20.1.3.1. Overview
            20.1.3.2. Product Portfolio
            20.1.3.3. Profitability by Market Segments
            20.1.3.4. Sales Footprint
            20.1.3.5. Strategy Overview
                20.1.3.5.1. Marketing Strategy
                20.1.3.5.2. Product Strategy
                20.1.3.5.3. Channel Strategy
        20.1.4. Sun Pharmaceutical Industries Ltd.
            20.1.4.1. Overview
            20.1.4.2. Product Portfolio
            20.1.4.3. Profitability by Market Segments
            20.1.4.4. Sales Footprint
            20.1.4.5. Strategy Overview
                20.1.4.5.1. Marketing Strategy
                20.1.4.5.2. Product Strategy
                20.1.4.5.3. Channel Strategy
        20.1.5. AstraZeneca Plc
            20.1.5.1. Overview
            20.1.5.2. Product Portfolio
            20.1.5.3. Profitability by Market Segments
            20.1.5.4. Sales Footprint
            20.1.5.5. Strategy Overview
                20.1.5.5.1. Marketing Strategy
                20.1.5.5.2. Product Strategy
                20.1.5.5.3. Channel Strategy
        20.1.6. Merck & Co., Inc.
            20.1.6.1. Overview
            20.1.6.2. Product Portfolio
            20.1.6.3. Profitability by Market Segments
            20.1.6.4. Sales Footprint
            20.1.6.5. Strategy Overview
                20.1.6.5.1. Marketing Strategy
                20.1.6.5.2. Product Strategy
                20.1.6.5.3. Channel Strategy
        20.1.7. Viatris + Mylan N.V
            20.1.7.1. Overview
            20.1.7.2. Product Portfolio
            20.1.7.3. Profitability by Market Segments
            20.1.7.4. Sales Footprint
            20.1.7.5. Strategy Overview
                20.1.7.5.1. Marketing Strategy
                20.1.7.5.2. Product Strategy
                20.1.7.5.3. Channel Strategy
        20.1.8. Cipla Inc.
            20.1.8.1. Overview
            20.1.8.2. Product Portfolio
            20.1.8.3. Profitability by Market Segments
            20.1.8.4. Sales Footprint
            20.1.8.5. Strategy Overview
                20.1.8.5.1. Marketing Strategy
                20.1.8.5.2. Product Strategy
                20.1.8.5.3. Channel Strategy
        20.1.9. Dr Reddy’s Laboratories Ltd.
            20.1.9.1. Overview
            20.1.9.2. Product Portfolio
            20.1.9.3. Profitability by Market Segments
            20.1.9.4. Sales Footprint
            20.1.9.5. Strategy Overview
                20.1.9.5.1. Marketing Strategy
                20.1.9.5.2. Product Strategy
                20.1.9.5.3. Channel Strategy
        20.1.10. Samsung Biologics
            20.1.10.1. Overview
            20.1.10.2. Product Portfolio
            20.1.10.3. Profitability by Market Segments
            20.1.10.4. Sales Footprint
            20.1.10.5. Strategy Overview
                20.1.10.5.1. Marketing Strategy
                20.1.10.5.2. Product Strategy
                20.1.10.5.3. Channel Strategy
        20.1.11. Abbott Laboratories
            20.1.11.1. Overview
            20.1.11.2. Product Portfolio
            20.1.11.3. Profitability by Market Segments
            20.1.11.4. Sales Footprint
            20.1.11.5. Strategy Overview
                20.1.11.5.1. Marketing Strategy
                20.1.11.5.2. Product Strategy
                20.1.11.5.3. Channel Strategy
21. Assumptions & Acronyms Used
22. Research Methodology
Recommendations

Healthcare

Microneedle Drug Delivery Systems Market

June 2024

REP-GB-2750

345 pages

Healthcare

Needle-Free Injectors Market

October 2022

REP-GB-13960

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Injectable Drug Market

Schedule a Call